MORF Live signals | Maximize Profits with Getagraph.com

SELL 92347 min ago

@ $37.26

Issued: 14 Feb 2024 @ 15:46

Return: -26.17%

Previous signal: Feb 14 - 14:06

Previous signal: Buy

Return: 0.38 %

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

Stats
Today's Volume	295 525
Average Volume	503 774
Market Cap	1.38B
EPS	$0 ( 2024-02-22 )
Next earnings date	( $-0.960 ) 2024-04-23
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.66
ATR14	$0.0460 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-27	Rogers Bruce	Buy	7 400	Common Stock
2024-03-27	Rogers Bruce	Sell	7 400	Stock Option (right to buy Common Stock)
2024-03-18	Cooper Simon Peter	Buy	170 000	Employee Stock Options (right to buy)
2024-03-18	Cooper Simon Peter	Buy	14 000	Restricted Stock Unit
2024-03-18	Cooper Simon Peter	Buy	7 000	Restricted Stock Unit

INSIDER POWER
69.60
Last 99 transactions
Buy: 2 671 692 \| Sell: 511 174

Volume Correlation

Long: -0.01 (neutral)

Short: -0.67 (moderate negative)

Signal:(40.501) Neutral

Morphic Holding Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Morphic Holding Inc Correlation - Currency/Commodity

0.09
( neutral )

0.55
( weak )

0.00
( neutral )

0.29
( neutral )

-0.19
( neutral )

0.49
( neutral )

Morphic Holding Inc Financials

Annual	2023
Revenue:	$521 000
Gross Profit:	$-570 000 (-109.40 %)
EPS:	$-3.59

Q4	2023
Revenue:	$-60.24M
Gross Profit:	$-60.52M (100.46 %)
EPS:	$-0.820

Q3	2023
Revenue:	$0
Gross Profit:	$-286 000 (0.00 %)
EPS:	$-0.730

Q2	2023
Revenue:	$60.24M
Gross Profit:	$59.97M (99.56 %)
EPS:	$-0.920

Financial Reports:

No articles found.

Morphic Holding Inc

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Realtime updates for Morphic Holding Inc [MORF]

Upcoming Earnings Alert